Evidence map›Paper›PMID 38932413›Full record

ArticleVaccines2024

Field Trials of Live and Inactivated Camelpox Vaccines in Kazakhstan.

Muratbay Mambetaliyev, Sanat Kilibayev, Marzhan Kenzhebaeva, Nuraiym Sarsenkulova, Shalkar Tabys, Aisulu Valiyeva, Dias Muzarap, Moldir Tuyskanova, Balzhan Myrzakhmetova, Nurkuisa Rametov and 5 more

Abstract read
In one paragraph

Article in Vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Muratbay MambetaliyevResearch Institute for Biological Safety Problems, Gvardeiysky 080409, Kazakhstan.
Sanat KilibayevResearch Institute for Biological Safety Problems, Gvardeiysky 080409, Kazakhstan.
Marzhan KenzhebaevaResearch Institute for Biological Safety Problems, Gvardeiysky 080409, Kazakhstan.
Nuraiym SarsenkulovaResearch Institute for Biological Safety Problems, Gvardeiysky 080409, Kazakhstan.
Shalkar TabysResearch Institute for Biological Safety Problems, Gvardeiysky 080409, Kazakhstan.
Aisulu ValiyevaResearch Institute for Biological Safety Problems, Gvardeiysky 080409, Kazakhstan.
Dias MuzarapResearch Institute for Biological Safety Problems, Gvardeiysky 080409, Kazakhstan.
Moldir TuyskanovaResearch Institute for Biological Safety Problems, Gvardeiysky 080409, Kazakhstan.
Balzhan MyrzakhmetovaResearch Institute for Biological Safety Problems, Gvardeiysky 080409, Kazakhstan.
Nurkuisa RametovInstitute of Ionosphere, Almaty 050020, Kazakhstan.ORCID 0000-0002-8346-4147
Aizhamal SarbassovaDepartment of Social Sciences, Satpayev Kazakh National Research Technical University, Almaty 050013, Kazakhstan.
Ryspek NurgazievDepartment of Infectious Animal Diseases, Skryabin Kyrgyz State Agrarian University, Bishkek 720000, Kyrgyzstan.
Aslan KerimbayevResearch Institute for Biological Safety Problems, Gvardeiysky 080409, Kazakhstan.
Shawn BabiukNational Centre for Foreign Animal Disease, Canadian Food Inspection Agency, Winnipeg, MB R3E 3M4, Canada.ORCID 0000-0003-1265-7264
Kuandyk ZhugunissovResearch Institute for Biological Safety Problems, Gvardeiysky 080409, Kazakhstan.ORCID 0000-0003-4238-5116

Funding

Science Committee of the Ministry of Science and Higher Education of the Republic of Kazakhstan AP09258770
6 · The paper itself

Abstract

An outbreak of camelpox occurred in the Mangistau region of Kazakhstan in 2019. To control the outbreak of camelpox and to prevent its further spread to other regions, camels were vaccinated using live and inactivated camelpox vaccines produced in Kazakhstan. To evaluate the efficacy of these camelpox vaccines in the field, vaccine trials used 172 camels on camel farms in the Beineu district. Of these, 132 camels were vaccinated using a live attenuated camelpox vaccine and 40 camels were vaccinated using an inactivated vaccine to observe immunogenicity and safety. The live vaccine was inoculated into camels by scarification at a dose of 5 × 10

Indexed as

camelpoxfield trialimmunogenicityinactivated vaccinelive vaccinesafetyscarification

Identifiers

PMID38932413
PMCPMC11209348

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.